Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2008 2
2009 2
2010 6
2011 2
2012 4
2013 7
2014 8
2015 2
2016 3
2017 5
2018 10
2019 9
2020 10
2021 10
2022 6
2023 2
2024 2
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening.
Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, Andreu M, Carballo F, Morillas JD, Hernández C, Jover R, Montalvo I, Arenas J, Laredo E, Hernández V, Iglesias F, Cid E, Zubizarreta R, Sala T, Ponce M, Andrés M, Teruel G, Peris A, Roncales MP, Polo-Tomás M, Bessa X, Ferrer-Armengou O, Grau J, Serradesanferm A, Ono A, Cruzado J, Pérez-Riquelme F, Alonso-Abreu I, de la Vega-Prieto M, Reyes-Melian JM, Cacho G, Díaz-Tasende J, Herreros-de-Tejada A, Poves C, Santander C, González-Navarro A; COLONPREV Study Investigators. Quintero E, et al. N Engl J Med. 2012 Feb 23;366(8):697-706. doi: 10.1056/NEJMoa1108895. N Engl J Med. 2012. PMID: 22356323 Free article. Clinical Trial.
Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial.
Castells A, Quintero E, Bujanda L, Castán-Cameo S, Cubiella J, Díaz-Tasende J, Lanas Á, Ono A, Serra-Burriel M, Frías-Arrocha E, Hernández C, Jover R, Andreu M, Carballo F, Morillas JD, Salas D, Almazán R, Alonso-Abreu I, Banales JM, Hernández V, Portillo I, Vanaclocha-Espí M, de la Vega M; COLONPREV study investigators. Castells A, et al. Among authors: portillo i. Lancet. 2025 Apr 12;405(10486):1231-1239. doi: 10.1016/S0140-6736(25)00145-X. Epub 2025 Mar 27. Lancet. 2025. PMID: 40158525 Clinical Trial.
Effectiveness and tolerability of intravenous fosfomycin in treating complicated urinary tract infections caused by Escherichia coli: a prospective cohort study from the FOSFOMIC project.
Moreno-Mellado E, Aslan AT, Akova M, León E, Merchante N, Vinuesa D, Moral-Escudero E, Sadyrbaeva-Dolgova S, López-Cárdenas S, Cano-Yuste Á, Rinaldi M, Núñez-Núñez M, Giannella M, Sojo-Dorado J, Antolí-Royo AC, Chacón N, Merino-Bohórquez V, Portillo I, Rodríguez-Baño J, Docobo-Pérez F, Gutiérrez-Gutiérrez B; FOSFOMIC team. Moreno-Mellado E, et al. Among authors: portillo i. Clin Microbiol Infect. 2025 May;31(5):839-846. doi: 10.1016/j.cmi.2025.01.007. Epub 2025 Jan 18. Clin Microbiol Infect. 2025. PMID: 39832652
83 results